Cargando…

The Contrasting Perceptions and the Cause Regarding Patenting Technologies Between Academic Medical Researchers and Pharmaceutical Companies Based in Japan

BACKGROUND: The recent trend of pharmaceutical companies commercializing new objects as new drugs based on the findings of academic medical researchers, commonly categorizing them as “academic drug discovery” is increasingly gaining popularity in the pharmaceutical industry. Studies state that acade...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugimitsu, Kazunari, Manome, Yoshinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286079/
https://www.ncbi.nlm.nih.gov/pubmed/34285498
http://dx.doi.org/10.2147/JMDH.S321834
_version_ 1783723670894542848
author Sugimitsu, Kazunari
Manome, Yoshinobu
author_facet Sugimitsu, Kazunari
Manome, Yoshinobu
author_sort Sugimitsu, Kazunari
collection PubMed
description BACKGROUND: The recent trend of pharmaceutical companies commercializing new objects as new drugs based on the findings of academic medical researchers, commonly categorizing them as “academic drug discovery” is increasingly gaining popularity in the pharmaceutical industry. Studies state that academic researchers based in universities have lower motivation to apply for patents. However, none of the studies evaluated the existence and extent of the “motivation for patent” in academic researchers, being lower than that of pharmaceutical companies. This study assesses two hypotheses; H1: academic medical researchers are less likely to believe that the patent system is necessary for pharmaceuticals, and thus have diminished interest in the commercialization of their research findings when compared to those in the pharmaceutical industry, H2: apprehension of the raison d’être of the patent system affects positive impressions on patents among academic medical researchers. METHODS: From February to March 2020, an anonymous survey was conducted among academic medical researchers, pharmaceutical industry professionals, and IP researchers based in Japan. Overall response rate was 27.4% (192/700). We conducted an analysis of variance for H1 and used the PLS-SEM model for H2 in order to verify the hypotheses. RESULTS: The results confirmed that the mean calculated from the responses of the academic medical researchers was significantly lower than the mean of pharmaceutical company personnel when responses to patenting an emerging technology or drug for the advancement of medicine were analyzed. In addition, we found that a causal relationship between academic medical researchers’ understanding of patents and their positive impressions on patents, depending on the degree to which they consider that the patent system is to encourage and promote new inventions. CONCLUSION: We conclude that a contrasting perception of patents not only exists between academic medical researchers and pharmaceutical company personnel but also it is caused by their apprehension of patents. More efforts to promote the raison d’être of the patent system among academic medical researchers will enable them to view pharmaceutical patents in a more positive light. Through this study, the pertinence to promote academic drug discoveries has been uncovered.
format Online
Article
Text
id pubmed-8286079
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82860792021-07-19 The Contrasting Perceptions and the Cause Regarding Patenting Technologies Between Academic Medical Researchers and Pharmaceutical Companies Based in Japan Sugimitsu, Kazunari Manome, Yoshinobu J Multidiscip Healthc Original Research BACKGROUND: The recent trend of pharmaceutical companies commercializing new objects as new drugs based on the findings of academic medical researchers, commonly categorizing them as “academic drug discovery” is increasingly gaining popularity in the pharmaceutical industry. Studies state that academic researchers based in universities have lower motivation to apply for patents. However, none of the studies evaluated the existence and extent of the “motivation for patent” in academic researchers, being lower than that of pharmaceutical companies. This study assesses two hypotheses; H1: academic medical researchers are less likely to believe that the patent system is necessary for pharmaceuticals, and thus have diminished interest in the commercialization of their research findings when compared to those in the pharmaceutical industry, H2: apprehension of the raison d’être of the patent system affects positive impressions on patents among academic medical researchers. METHODS: From February to March 2020, an anonymous survey was conducted among academic medical researchers, pharmaceutical industry professionals, and IP researchers based in Japan. Overall response rate was 27.4% (192/700). We conducted an analysis of variance for H1 and used the PLS-SEM model for H2 in order to verify the hypotheses. RESULTS: The results confirmed that the mean calculated from the responses of the academic medical researchers was significantly lower than the mean of pharmaceutical company personnel when responses to patenting an emerging technology or drug for the advancement of medicine were analyzed. In addition, we found that a causal relationship between academic medical researchers’ understanding of patents and their positive impressions on patents, depending on the degree to which they consider that the patent system is to encourage and promote new inventions. CONCLUSION: We conclude that a contrasting perception of patents not only exists between academic medical researchers and pharmaceutical company personnel but also it is caused by their apprehension of patents. More efforts to promote the raison d’être of the patent system among academic medical researchers will enable them to view pharmaceutical patents in a more positive light. Through this study, the pertinence to promote academic drug discoveries has been uncovered. Dove 2021-07-12 /pmc/articles/PMC8286079/ /pubmed/34285498 http://dx.doi.org/10.2147/JMDH.S321834 Text en © 2021 Sugimitsu and Manome. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sugimitsu, Kazunari
Manome, Yoshinobu
The Contrasting Perceptions and the Cause Regarding Patenting Technologies Between Academic Medical Researchers and Pharmaceutical Companies Based in Japan
title The Contrasting Perceptions and the Cause Regarding Patenting Technologies Between Academic Medical Researchers and Pharmaceutical Companies Based in Japan
title_full The Contrasting Perceptions and the Cause Regarding Patenting Technologies Between Academic Medical Researchers and Pharmaceutical Companies Based in Japan
title_fullStr The Contrasting Perceptions and the Cause Regarding Patenting Technologies Between Academic Medical Researchers and Pharmaceutical Companies Based in Japan
title_full_unstemmed The Contrasting Perceptions and the Cause Regarding Patenting Technologies Between Academic Medical Researchers and Pharmaceutical Companies Based in Japan
title_short The Contrasting Perceptions and the Cause Regarding Patenting Technologies Between Academic Medical Researchers and Pharmaceutical Companies Based in Japan
title_sort contrasting perceptions and the cause regarding patenting technologies between academic medical researchers and pharmaceutical companies based in japan
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286079/
https://www.ncbi.nlm.nih.gov/pubmed/34285498
http://dx.doi.org/10.2147/JMDH.S321834
work_keys_str_mv AT sugimitsukazunari thecontrastingperceptionsandthecauseregardingpatentingtechnologiesbetweenacademicmedicalresearchersandpharmaceuticalcompaniesbasedinjapan
AT manomeyoshinobu thecontrastingperceptionsandthecauseregardingpatentingtechnologiesbetweenacademicmedicalresearchersandpharmaceuticalcompaniesbasedinjapan
AT sugimitsukazunari contrastingperceptionsandthecauseregardingpatentingtechnologiesbetweenacademicmedicalresearchersandpharmaceuticalcompaniesbasedinjapan
AT manomeyoshinobu contrastingperceptionsandthecauseregardingpatentingtechnologiesbetweenacademicmedicalresearchersandpharmaceuticalcompaniesbasedinjapan